SCHEMBL20134933

SCHEMBL20134933

COc1cc(C(=O)N2CCN(c3nc(C)c(C)cc3C)CC2)ccc1C1(C(C)C)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
ATM Q13315 1/20 0.41
LMNA P02545 6/20 0.40
TSHR P16473 1/20 0.39
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
NR3C1 P04150 1/20 0.38
PGR P06401 1/20 0.38
SLC6A4 P31645 1/20 0.38
KCNH2 Q12809 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
PKM P14618 1/20 0.38
MMP2 P08253 1/20 0.37
ADAM17 P78536 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
POLB P06746 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688232 1.00 MAPT (0.41) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL20134983 0.91 ADAMTS5 (0.37) MAPTSMN1; SMN2LMNATSHRALDH1A1
SCHEMBL29688815 0.91 ADAMTS5 (0.37) MAPTSMN1; SMN2LMNATSHRALDH1A1
SCHEMBL29688842 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL20135127 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL29689268 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL20135123 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL20135401 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL29689282 0.88 LMNA (0.44) MAPTSMN1; SMN2GAAATMLMNA
SCHEMBL20134817 0.85 ALDH1A1 (0.37) MAPTSMN1; SMN2LMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US claimed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US claimed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP claimed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885SMN1; SMN2 2532/4885GAA 1697/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885SMN1; SMN2 2476/4885GAA 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.